FDA leaders say one pivotal trial, not two, should be ‘default’ for drug approvals
FDA leaders say one pivotal trial, not two, should be ‘default’ for drug approvals
Contenido no disponible. Consulta la fuente original.
FDA leaders say one pivotal trial, not two, should be ‘default’ for drug approvals